BCAT-IN-4 Secrets
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine to evaluate a number of intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Most important demo targets were to evaluate the security and tolerability of sifalimumab in dermatomyositis or pol